Form 4: ResMed CEO Sells Shares Under 10b5-1 Plan

ResMed Inc. Chairman and CEO Michael J. Farrell reported the sale of 4,991 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael J. Farrell, Chairman and CEO of ResMed Inc., sold 4,991 shares of ResMed Common Stock on June 8, 2026.
• The sale was executed under a Rule 10b5-1 trading plan adopted on October 31, 2024, which is designed to comply with affirmative defense conditions.
• The weighted average sale price for these shares was $193.962, with individual trades ranging from $192.605 to $194.715.
• Following this transaction, Farrell beneficially owns 466,256 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
• Additionally, the filing notes the acquisition of 32,671 shares through the ResMed Employee Stock Purchase Plan on April 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the CEO selling a notable number of shares, despite the transaction being conducted under a pre-arranged 10b5-1 plan.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading related activity.
• The company continues to facilitate employee stock ownership through its Employee Stock Purchase Plan.

Negatives

• A significant number of shares were sold by the CEO, which could be perceived negatively by the market, despite being under a 10b5-1 plan.

Risks

• Potential for negative market perception due to insider selling, even if executed under a pre-arranged plan.
• The Rule 10b5-1 plan itself is subject to specific conditions and regulatory scrutiny.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
• This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price.
• Includes 32,671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event for executives in the healthcare technology sector. Such plans are designed to allow executives to diversify their holdings or meet financial obligations without creating the appearance of trading on material non-public information. However, the volume and timing can still influence investor sentiment.

Stakeholder Impact

• Shareholders: May perceive the CEO's sale as a negative signal, potentially impacting short-term stock price, although the 10b5-1 plan mitigates this concern to some extent.
• Employees: The purchase of shares through the Employee Stock Purchase Plan indicates continued employee engagement and investment in the company.
• Management: The transaction is a routine part of executive financial planning and does not indicate a change in management's strategic outlook.

Next Steps

• Continued monitoring of Michael J. Farrell's beneficial ownership and any future transactions.
• Observation of market reaction to the reported share sale.

Key Dates

Recommendation

The filing reports a stock sale by the CEO under a Rule 10b5-1 plan, which is a standard practice and does not inherently signal a negative outlook for the company's future performance. While insider selling can be a concern, the pre-planned nature of this transaction suggests it's for personal financial management rather than a reflection of company fundamentals. Therefore, a 'hold' recommendation is appropriate pending further information or performance indicators.

Keywords

ResMed, RMD, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Michael J. Farrell, CEO, Beneficial Ownership, Employee Stock Purchase Plan